Perioperative and Survival Outcomes of Robotic-Assisted Surgery, Comparison with Laparoscopy and Laparotomy, for Ovarian Cancer: A Network Meta-Analysis

Table 2

Characteristics of included studies.

Study	Study year	Location	Stage	Group	N.	OS	Outcomes	Study design	Bias score	Follow up(m)
1 Chi [24] 2005	2000-2003	USA	I	LS	20		①②③⑥	Retrospective cohort	7	NA
				LT	30
2 Ke-qin Hua [25] 2005	2002-2004	China	I	LS	10		③④⑤⑥⑨	Retrospective cohort	6	NA
				LT	11
3 Ghezzi [26] 2007	1997-2003	Italy	I	LS	15		①②③④⑤⑥⑦⑧⑩	Retrospective cohort	7	4-108
				LT	19
4 Jeong-Yeol Park [27] 2008	2004-2007	Korea	I	LS	19		①②③④⑤⑥⑦⑧⑨⑩	Prospective cohort	7	1-44
				LT	33
5 Jeong-Yeol Park [28] 2008	2001-2006	Korea	I	LS	17		①②③④⑤⑥⑦⑧⑨⑩	Retrospective cohort	7	5-61
				LT	19
6 Tzu-I Wu [29] 2010	1984-2006	Taiwan	I	LS	34	√	——	Retrospective cohort	8	2-276
				LT	174
7 Magrina [30] 2011	2002-2008	USA	NA	R	25		③④⑤⑥⑦⑧	Retrospective case–control	8	1-128
				LS	27
				LT	119
8 Feuer [31] 2013	2008-2012	USA	I-IV	RAS	63		②③④⑤⑥⑨	Retrospective cohort	7	12
				LT	26
9 Gremeau [32] 2014	1989-2009	France	I-IV	LS	7		②	Retrospective cohort	8	8-240
				LT	13
10 Nezhat [15] 2014	2008-2012	USA	I	RAS	9		③④⑤⑥	Retrospective cohort	8	NA
				LS	10
				LT	3
11 Nezhat [15] 2014	2008-2012	USA	II-IV	RAS	10		③④⑤⑥⑩	Retrospective cohort	8	NA
				LS	29
				LT	8
12 Bogani [33] 2014	2003-2010	Italy	I-III	LS	35	√	①②③④⑤⑥⑦⑧⑩	Retrospective cohort	8	37-278
				LT	32
13 Liu [34] 2014	2002-2010	China	I-II	LS	35		②③⑨	Retrospective cohort	8	36-84
				LT	40
14 Zhang [35] 2014	2010-2013	China	I-III	LS	15	√	②③⑤⑥⑨	Retrospective cohort	6	NA
				LT	20
15 Yu-Jin Koo [36] 2014	2006-2012	Korea	I-II	LS	24		①②③⑦⑧	Retrospective cohort	8	>60
				LT	53
16 Favero [37] 2015	2011-2014	Germany	IIIc–IVa	LS	10		②③⑤⑥⑩	Prospective cohort	7	34
				LT	11
17 Chen [38] 2015	2005-2014	Taiwan	IA–IIIC	RAS	44		②③④⑤⑥⑨⑩	Retrospective cohort	7	29.6
				LS	21
				LT	73
18 Bellia [39] 2016	2006-2014	Italy	I-III	RAS	16		②③④⑤⑥⑦⑧	Retrospective cohort	7	4-42
				LS	23
19 Minig [40] 2016	2006-2014	Spain/Argentina	I-IV	LS	50	√	①②③④⑤⑥⑦⑧⑩	Retrospective cohort	8	>60
				LT	58
20 Ditto [41] 2016	2005-2015	Italy	I	LS	50	√	①②③④⑤⑥⑦⑧⑩	Retrospective cohort	8	>60
				LT	50
21 Lu [42] 2016	2002-2014	China	I-III	LS	42	√	①②③④⑤⑥⑦⑧⑨⑩	Retrospective cohort	8	16–152
				LT	50
22 Gallotta [43] 2016	2014-2016	Italy	I	RAS	32		①②③④⑤⑥⑦⑧⑨	Case-control	6	NA
				LS	64
23 Gallotta [44] 2016	2000-2013	Italy	I	LS	60	√	②⑨	Retrospective cohort	7	48
				LT	120
24 Gueli Alletti [45] 2016	2013-2014	Rome	I-IV	LS	30		①②③④⑤⑥	Retrospective case-control	7	24
				LT	65
25 Xiong Wei [46] 2017	2007-2014	China	I-II	LS	71	√	①②③⑥⑦⑧⑩	Retrospective cohort	8	3-103
				LT	31
26 Ye Mingxia [47] 2017	2014-2015	China	I	RAS	9		①②③④⑤⑥⑨	Retrospective cohort	8	12-24
				LS	10
				LT	8
27 Huamao Liang [48] 2017	2007-2016	China	II-IV	LS	64	√	③④⑤⑥⑦⑧⑩	Retrospective cohort	8	5-122
				LT	68
28 Ceccaroni [49] 2017	2007-2015	Italy	III–IV	LS	21		②③④⑤⑥⑩	Prospective cohort	8	>100
				LT	45
29 Melamed [50] 2017	2010-2012	USA	IIIC-IV	LS	450	√	NA	Retrospective cohort	7	60
				LT	2621
30 Nam [51] 2017	2001-2014	Korea	I-II	LS	25	√	①③④⑤⑥⑦⑧	Retrospective cohort	8	>60
				LT	24
31 Brown [52] 2018	2006-2017	USA	III-IV	LS	53	√	①②③⑩	Retrospective cohort	7	>100
				LT	104
32 Bergamini [53] 2018	1965-2017	Italy	I	LS	93	√	——	Retrospective cohort	7	>200
				LT	130
33 Chen Shuying [54] 2019	2015-2018	China	III-IV	RAS	32	√	①②③⑥	Retrospective cohort	8	7-36
				LS	30
34 Jeremie [55] 2019	2008-2014	Canada	III–IV	RAS	57	√	①⑩	Retrospective cohort	7	>60
				LT	34
35 Facer [56] 2019	2010-2014	USA	I	RAS	636	√	②⑨	Retrospective cohort	7	>60
				LS	1265
36 Sang [57] 2020	2008-2017	Korea	I-IV	LS	57		③⑥⑩	Retrospective cohort	7	NA
				LT	192
37 Baiomy [58] 2020	2016-2019	Egypt	I-III	LS	30		①②③④⑤⑥⑦⑧	Retrospective cohort	7	36
				LT	30
38 She Yujia [59] 2020	2013-2018	China	NA	RAS	33		①③④⑤⑥⑦⑧⑨⑩	Retrospective cohort	8	8-56
				LS	52
				LT	75
39 Margaux Merlier [60] 2020	2000-2018	French	I-II	LS	37	√	④⑤⑥	Retrospective cohort	8	18-58
				LT	107

Note: ① estimated blood loss: EBL/ml; ② length of hospital stay: LHS/days; ③ operating time: OT/min; ④ postoperative complication; ⑤ intraoperative complication; ⑥ total complication; ⑦ pelvic lymph nodes; ⑧ para-aortic lymph nodes; ⑨ total lymph nodes; ⑩ transfusion; OS: overall survival (five years); NA: not available.